IsoPlexis Bolsters Its Global Operational and Product Support Leadership

Rhea-AI Summary

IsoPlexis (NASDAQ: ISO) announced the addition of Michelle Reid, Ph.D. as VP of Service and Support, and Anthony Catalano as Senior VP of Operations. These strategic appointments aim to enhance operational excellence and customer support as the company focuses on global expansion. Reid brings over 20 years of experience in customer experience for molecular products, while Catalano has extensive operations expertise from PerkinElmer. CEO Sean Mackay highlighted the importance of these roles in driving innovation and addressing customer needs in the proteomics market.

Positive

• Appointment of experienced leaders to enhance operational excellence and customer support.
• Michelle Reid and Anthony Catalano bring over 20 years of relevant experience.
• Focus on global expansion and innovation in the proteomics market.

Negative

• None.

BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support.

Ms. Reid comes to IsoPlexis with over 20 years of experience leading and developing customer experience teams for regulated and non-regulated molecular products and a Ph.D in Molecular Biology from LaTrobe University in Australia. Previously, she was the Senior Director of Customer Service and Support at PGDx, where she built the customer experience teams from the ground up. She was also a key player in the growth and development of the customer support team at QIAGEN, a global leader in sample and assay technologies for molecular diagnostics and life sciences research.

Before joining IsoPlexis, Mr. Catalano spent 11 years as Senior Director of Operations at PerkinElmer, Inc., a Massachusetts-based supplier of unique solutions to the diagnostics, life sciences, food, and applied markets. He also served as Senior Director of Manufacturing Operations at VisEn Medical Inc. from 2001 until its acquisition by PerkinElmer in 2010. Mr. Catalano has a background as a scientist and manufacturing engineer and an M.S. in Chemistry from Brandeis University.

"We are excited to have Michelle and Anthony join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "As we enter the next phase of our growth, our new hires will help us continue to drive operational excellence and deliver important innovations to the market. Their depth of experience will help us continue our global expansion and customer focus worldwide."

About IsoPlexis

IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.

Cautionary Note Regarding Forward Looking Statements

Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: the rate of adoption of the Company's technology by its customers and potential customers as well as the risk factors set forth in the Risk Factors section of the Company's prospectus filed with the SEC.  These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, IsoPlexis disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Investor Contact
investors@isoplexis.com

Press Contact
press@isoplexis.com

Related Links
www.isoplexis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/isoplexis-bolsters-its-global-operational-and-product-support-leadership-301422850.html

SOURCE IsoPlexis

FAQ

What are the new leadership positions announced by IsoPlexis?

IsoPlexis announced the appointment of Michelle Reid as VP of Service and Support and Anthony Catalano as Senior VP of Operations.

What experience does Michelle Reid bring to IsoPlexis?

Michelle Reid has over 20 years of experience in customer experience teams for molecular products and a Ph.D. in Molecular Biology.

Who is the new Senior VP of Operations at IsoPlexis?

Anthony Catalano is the new Senior VP of Operations at IsoPlexis, previously serving at PerkinElmer.

How will these new appointments impact IsoPlexis?

The appointments are expected to enhance operational excellence and improve customer support, aiding IsoPlexis in global expansion.

When was the press release about IsoPlexis' leadership changes published?

The press release was published on November 12, 2021.